Vasomotor Symptoms & Cardiometabolic Risk: Insights for Hormone Therapy

Uncover the effects of hormone therapy on vasomotor symptoms and cardiometabolic risk for better health outcomes.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through a clear, comprehensive journey into menopause, focusing on vasomotor symptoms—hot flashes and night sweats—and their underlying physiological roots. I present modern, evidence-based insights from leading researchers and standards such as the STRAW +10 staging system, explain the hormonal interplay among estrogen, FSH, progesterone, inhibin, and KNDy neurons, and clarify why, when, and how we use menopausal hormone therapy (MHT) alongside non-hormonal treatments. I also detail how our integrated team at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas—where I collaborate with Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933)—combines internal medicine oversight, integrative chiropractic care, functional medicine, rehabilitation, and personal injury care to deliver individualized, whole-person strategies. This post offers practical steps, clinical reasoning, and transparent, APA-7-style references to empower you with confidence and clarity.

Introducing Our Multidisciplinary Model of Care in El Paso, TX

I am honored to work in a multidisciplinary, patient-centered clinic that integrates medical and chiropractic expertise—an approach increasingly recognized as best practice in modern integrative and injury care.

• Medical Director and Collaborative Physician: Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine, with over 40 years of clinical experience (NPI #1164426749, Texas MD License #J2933), provides medical direction and oversight.
• Integrative Chiropractic Care: I lead the neuromusculoskeletal and functional assessment, offering targeted adjustments, soft-tissue work, and movement-based rehabilitation.
• Functional Medicine: We map root causes by analyzing hormonal balance, metabolic health, gut function, nutrient status, and genetic and biochemical factors.
• Rehabilitation and Personal Injury Care: Our team delivers evidence-based therapies to restore function after injuries and address biomechanics contributing to pain and disability.

This cohesive model allows us to tailor treatment to each patient’s physiology, symptoms, and goals—especially vital for women navigating menopause, in which hormonal changes ripple through the cardiovascular, skeletal, neurological, and genitourinary systems.

Understanding Menopause: Clear Definitions, Timelines, and Why It Matters

Menopause is a natural transition, not a disease. Precision in definitions ensures we deploy the right treatments at the right times.

• Menopause: Confirmed after 12 consecutive months without a menstrual period, marking the final menstrual period (FMP). The median age in the U.S. is about 52.5 years (Harlow et al., 2012).
• Perimenopause (Menopausal Transition): Typically begins between ages 45–55 and features fluctuating hormones and irregular cycles.
• Early and Premature Menopause: Before 45 is early; before 40 is premature. These distinctions matter for bone, heart, and metabolic health.
• Systemic Effects: Hormonal shifts affect the skeletal, cardiovascular, nervous, and genitourinary systems. Addressing only hot flashes misses the bigger picture.

Our approach uses the STRAW +10 criteria to align symptoms and timing with physiological stages, ensuring we match therapies to where you are on the journey (Harlow et al., 2012).

STRAW +10: A Practical Roadmap of Reproductive Aging

The Stages of Reproductive Aging Workshop (STRAW +10) helps us classify phases for precise counseling and management (Harlow et al., 2012).

• Reproductive Stages (−5 to −3): Regular cycles; subtle changes may begin late in this sequence.
• Early Transition (−2): Cycles vary by ≥7 days; FSH begins to rise as ovarian reserve declines.
• Late Transition (−1): Periods of ≥60 days amenorrhea; vasomotor symptoms intensify; FSH typically elevated (>25 IU/L).
• Postmenopause (+1, +2):

• • Early (+1): First six years after FMP; VMS often peak in the first two years.
  • Late (+2): VMS may persist or resolve. Some women experience symptoms for more than seven years on average.

Using STRAW +10 avoids overreliance on single lab values during periods of significant variability and guides risk-benefit decisions.

The Hormonal Symphony: Inhibin, FSH, Estrogen, Progesterone, and Androgens

Menopausal symptoms reflect a cascade of interrelated hormonal shifts. Understanding these reveals why certain therapies work—and how to use them safely.

• Inhibin: Declines early as ovarian follicle number and quality diminish. Without inhibin’s restraint, the pituitary increases FSH to stimulate the ovaries.
• FSH: Elevates in response to declining ovarian feedback. Levels are variable during transition; a single test is rarely diagnostic.
• Progesterone: Falls with fewer ovulatory cycles, contributing to irregular or missed periods and changes in mood and sleep.
• Estrogens:

• • Estradiol (E2): The most potent estrogen decreases markedly after menopause, contributing to VMS and genitourinary changes.
  • Estrone (E1): Becomes dominant after menopause; produced primarily in adipose tissue and adrenal conversion pathways; levels fall less dramatically than E2.

• Testosterone and DHEAS: Testosterone declines over time but often remains within the lower normal range; DHEAS is relatively stable throughout the menopausal transition.

Clinically, for a woman in her early 50s with classic symptoms and cycle changes, routine hormone testing is often unnecessary; diagnosis is clinical, and treatment is guided by symptoms and risk factors (Harlow et al., 2012; The NAMS 2022 Position Statement, 2022).

Why Hot Flashes Happen: The Thermoneutral Zone and KNDy Neurons

Vasomotor symptoms are not vague or imagined; they are rooted in measurable neuroendocrine changes.

• Thermoneutral Zone Narrowing: In the hypothalamus, the zone where the body neither sweats nor shivers shrinks significantly during menopause. Small shifts in core temperature trigger outsized heat-loss responses—flushing and sweating.
• KNDy Neurons: A specialized hypothalamic network—kisspeptin, neurokinin B (NKB), and dynorphin—mediates thermoregulation.

• • Estrogen as a Brake: Estradiol suppresses KNDy activity during reproductive years.
  • Brake Removal: As estrogen falls, NKB signaling is unopposed, KNDy neurons hyperfire, and the thermoregulation center becomes hypersensitive.

• Clinical Implications: This mechanism explains why certain SSRIs/SNRIs can help and why NK3 receptor antagonists represent a breakthrough non-hormonal option for VMS. It also supports individualized therapy when hormones are contraindicated or declined.

The prevalence is high—over 80% of women experience VMS, often beginning two years before FMP, and lasting on average more than seven years for many (Thurston et al., 2019). Severe, prolonged VMS is associated with increased cardiovascular risk, underscoring the need for active management.

Real-World Patient Story: “Miss Jenny” and the Journey to Restored Sleep

Patients like “Miss Jenny,” a 52-year-old professional, arrive exhausted from drenching night sweats, waking multiple times, and feeling discouraged. In my clinical experience, the path to relief begins with a thoughtful conversation:

• Menstrual History: The timing of the last period and cycle patterns guide staging.
• Associated Symptoms: Mood changes, sleep disruption, joint pain, genitourinary symptoms.
• Previous Attempts: Validate the journey—many have felt dismissed.

This narrative is common. Clear explanation of the physiology (thermoneutral zone, KNDy neurons, estrogen shifts) helps women feel seen and builds trust as we co-create a plan.

Treatment Spectrum: Lifestyle Foundations, Non-Hormonal Options, and MHT

There is no single path. We customize based on symptoms, risks, preferences, and stage.

• Lifestyle and Home Strategies

• • Cool sleeping environments, layered clothing, paced breathing.
  • Trigger awareness: spicy foods, alcohol, caffeine, high ambient heat.
  • Stress modulation and sleep hygiene: timing of light exposure, mindfulness.
  • Nutritional support: anti-inflammatory diet, hydration, magnesium and vitamin D sufficiency.

• Non-Hormonal Pharmacologic Therapies

• • SSRIs/SNRIs (e.g., low-dose paroxetine): Modulate central thermoregulation; useful when hormones are contraindicated (Stuenkel et al., 2015).
  • NK3R antagonists: Target NKB signaling in KNDy neurons, reducing VMS frequency and severity; a rapidly advancing option grounded in neuroendocrine science (The NAMS 2022 Position Statement, 2022).
  • Cognitive Behavioral Therapy (CBT): Decreases VMS severity and improves sleep and coping; access and cost can be barriers, but clinical benefit is real (Stuenkel et al., 2015).

• Menopausal Hormone Therapy (MHT)

• • Most effective for moderate-to-severe VMS, GSM, and bone loss prevention when appropriate and individualized (The NAMS 2022 Position Statement, 2022; Stuenkel et al., 2015).
  • Indications: VMS relief; bone-loss prevention; hypoestrogenism due to premature/early menopause; GSM (local therapy if isolated GSM).
  • Contraindications and Cautions: Prior estrogen-sensitive cancer, undiagnosed bleeding, active liver disease, recent arterial thrombosis, uncontrolled hypertension, and careful consideration in the presence of VTE history—prefer transdermal routes when indicated (The NAMS 2022 Position Statement, 2022; Vinogradova et al., 2020).

Our reasoning: match the mechanism to the symptom and risk profile; start low and adjust thoughtfully; prefer safer routes (transdermal); protect the endometrium (progesterone); monitor diligently.

Modern MHT: Transdermal First, Progesterone Protection, and Personalization

Contemporary evidence has clarified that route and formulation matter greatly.

• Transdermal Estrogen Advantages

• • Bypasses first-pass hepatic metabolism; less induction of clotting factors; lower risk of DVT and stroke compared with oral forms (Vinogradova et al., 2020; The NAMS 2022 Position Statement, 2022).
  • Delivery forms: patches, gels, and mists with steady absorption; dosing titrated to effect.
  • Clinical pearls: allow gels/mists to dry fully for reliable uptake; rotate patch sites to protect skin.

• Progestin Necessity with an Intact Uterus

• • Unopposed estrogen stimulates the endometrium and increases risk of hyperplasia/cancer.
  • Micronized progesterone is preferred for endometrial protection and better tolerability; combination patches are convenient for some but may be associated with more breakthrough bleeding (Stuenkel et al., 2015; The NAMS 2022 Position Statement, 2022).

• Oral Estrogen and Combination Options

• • Appropriate for women post-hysterectomy (estrogen-only) or those preferring oral regimens; risks must be weighed and minimized by dosing and timing.
  • Switching progestin type can address mood effects or intolerances; shared decision-making is essential.

• SERMs and Parenteral Therapies

• • Conjugated estrogen plus bazedoxifene (a SERM): Estrogen agonism in bone; antagonism in uterus/breast; addresses VMS and bone health without separate progestin (Lobo, 2017).
  • Parenteral estradiol (valerate or cypionate): Reserved for refractory cases or specific clinical contexts; pharmacokinetic differences can personalize peaks and symptom coverage.

Why this matters: tailoring the route and formulation optimizes efficacy and safety, aligns with the timing hypothesis, and supports long-term health goals beyond symptom relief.

---

Aligned & Empowered: Chiropractic Conversations on Women’s Health- Video

---

Risks, Side Effects, and Monitoring: Putting Safety in Perspective

Accurate risk framing helps patients make confident decisions.

• Early Side Effects: Temporary breast tenderness, spotting, bloating, or mild headaches commonly resolve within 3–6 months; dosing adjustments often help.
• Stroke and DVT: Risk is increased with oral estrogens; transdermal routes minimize this and are preferred in higher-risk individuals (Vinogradova et al., 2020).
• Endometrial Protection: Always add a progestogen if the uterus is present; micronized progesterone is my choice for safety and tolerability.
• Breast Health Risk:

• • Estrogen-alone in hysterectomized women shows low, if any, increased risk.
  • Combined estrogen-progestin carries a small incremental risk after several years; using micronized progesterone may reduce that relative risk compared to synthetic progestins (The NAMS 2022 Position Statement, 2022; Lobo, 2017).

• Monitoring: Annual mammograms, clinical breast exams, blood pressure checks, and periodic reassessment of dose, route, and need ensure ongoing safety.

Clinical reasoning: We leverage transdermal estrogen to minimize thrombotic risk, use micronized progesterone for endometrial protection and a potentially better breast risk profile, and establish structured follow-ups for proactive adjustment.

Integrative Chiropractic Care: The Neuro-Musculoskeletal Link to Hormonal Health

My role as a chiropractor within our integrated team is to optimize the structural and neurological platforms upon which endocrine balance depends.

• Spinal Biomechanics and Nervous System Tone

• • Targeted adjustments restore segmental motion and reduce nociceptive load that can amplify sympathetic overdrive.
  • Balancing autonomic tone may improve sleep quality, stress resilience, and perceived severity of VMS through central modulation.

• Musculoskeletal Pain and Function

• • Estrogen decline is linked to joint pain, stiffness, and accelerated bone loss. Manual therapy, soft-tissue techniques, and precision rehabilitation reduce pain, improve mechanics, and support safe strength training to maintain bone density.

• Functional Nutrition and Lifestyle

• • Anti-inflammatory dietary strategies, magnesium, vitamin D, omega-3s, and protein support musculoskeletal and endocrine health.
  • We help identify dietary triggers of hot flashes and personalize plans that stabilize glycemic and autonomic responses.

From my clinical observations (see dralexjimenez.com and my LinkedIn profile), women who integrate chiropractic care with MHT or non-hormonal therapies often report improved sleep, reduced anxiety, and better exercise tolerance—synergistic gains that underpin sustainable outcomes.

Functional Medicine Integration: Addressing Root Causes That Magnify Symptoms

Functional medicine complements chiropractic and medical oversight by addressing upstream drivers.

• Adrenal–Stress Axis

• • Chronic stress can dysregulate cortisol rhythms, worsen sleep fragmentation, and exacerbate vasomotor reactivity. We deploy stress-modulating routines, breathwork, and circadian-aligned behaviors.

• Gut–Estrogen Axis

• • The estrobolome influences estrogen metabolism and re-circulation. Optimizing gut function—through fiber diversity, polyphenols, and probiotics—can improve hormonal balance and symptom control.

• Nutrient and Metabolic Health

• • Adequate magnesium, B vitamins, vitamin D, and omega-3s support neurotransmission, vascular health, and bone integrity.
  • We assess insulin resistance, lipid profiles, and inflammation markers to align MHT and lifestyle protocols with cardiometabolic risk reduction (Boardman et al., 2015).

Clinical reasoning: By stabilizing the stress response, gut function, and nutrient terrain, we lower symptom burden and improve resilience, often reducing needed hormone doses while enhancing quality of life.

Genitourinary Syndrome of Menopause (GSM): Local and Systemic Solutions

GSM includes vaginal dryness, dyspareunia, atrophy, urinary urgency, and recurrent UTIs due to estrogen decline in urogenital tissues.

• Local Vaginal Estrogen

• • Creams, tablets, and rings deliver targeted estrogen with minimal systemic absorption, restoring tissue integrity, lubrication, and urethral support.
  • Particularly suitable when GSM is the primary complaint and systemic therapy is not needed.

• When VMS and GSM Coexist

• • Systemic MHT can address both; local estrogen may be added for focal symptoms.

Clinical rationale: local therapy is effective, low-risk, and enhances quality of life, sexual health, and urinary function without broad systemic exposure.

Cardiovascular and Metabolic Considerations: Timing and Benefits

Modern data refine the cardiovascular narrative of MHT.

• Timing Hypothesis

• • Starting MHT within 10 years of FMP or before age 60 is associated with improved cardiovascular profiles compared with later initiation (Stuenkel et al., 2015; The NAMS 2022 Position Statement, 2022).

• Metabolic Effects

• • MHT may improve lipid profiles and reduce the risk of incident type 2 diabetes in appropriate candidates (Boardman et al., 2015; Lobo, 2017).

• Bone Health

• • Estrogen preserves bone density; MHT reduces risk of osteopenia/osteoporosis, especially early after menopause when bone loss accelerates.

Clinical reasoning: timing aligns therapy with vascular pliability and lipid remodeling, maximizing benefit while minimizing risks.

Follow-Up, Dose Adjustments, and Long-Term Partnership

Menopause management is a dynamic process requiring collaborative, ongoing care.

• Initial Phase (First 3–6 Months)

• • Assess symptom relief, side effects, BP, and adherence; titrate dose or switch routes to optimize outcomes.

• Annual Review

• • Re-evaluate indications, risks, and goals; update imaging and labs as needed; consider tapering or continuing based on benefits and preferences.

• Multidisciplinary Collaboration

• • Coordinate with cardiology, oncology, neurology, and primary care when comorbidities or special considerations arise.

Our goal is for you to feel measurably better—sleep restored, mood steadied, pain reduced, life reclaimed. When a patient like Miss Jenny returns to say, “I can’t believe I’m sleeping through the night again,” it confirms that a personalized, integrative, evidence-based plan works.

Team Integration: How We Work Together for You

At Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic), our coordinated approach ensures no aspect of your care is overlooked.

• Medical Oversight (Dr. Cardenas, MD)

• • Diagnostic leadership; medication and MHT management; risk stratification; coordination with specialists.

• Integrative Chiropractic (Dr. Jimenez, DC)

• • Spinal adjustments; neuromuscular rehabilitation; soft-tissue therapies; ergonomics and movement training.

• Functional Medicine

• • Root-cause evaluation; advanced testing when appropriate; nutrition, sleep, stress, and gut restoration protocols.

• Rehabilitation and Personal Injury Care

• • Post-injury reconditioning; strength, balance, and bone loading programs tailored to menopausal physiology.

This integrated plan makes complex decisions simpler, safer, and more effective by aligning therapies across systems.

References

• Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging (Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., de Villiers, T. J., & STRAW+10 Collaborative Group, 2012). Menopause, 19(4), 387–395.
• The 2022 hormone therapy position statement of The North American Menopause Society (The NAMS 2022 Hormone Therapy Position Statement Advisory Panel, 2022). Menopause, 29(7), 767–794.
• Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline (Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J., 2015). The Journal of Clinical Endocrinology & Metabolism, 100(11), 3975–4011.
• Hormone-replacement therapy: current thinking (Lobo, R. A., 2017). Nature Reviews Endocrinology, 13(4), 220–231.
• Hormone therapy for preventing cardiovascular disease in post-menopausal women (Boardman, H. M., Hartley, L., Eisinga, A., Gomersall, T., Roalfe, A., & Stolk, R. P., 2015). Cochrane Database of Systematic Reviews, (3), CD002229.
• Hot flashes and cardiac vagal control during sleep (Thurston, R. C., Chang, Y., Buysse, D. J., Hall, M. H., & Matthews, K. A., 2019). Menopause, 26(9), 978–984.
• Use of hormone replacement therapy and risk of venous thromboembolism: Nested case-control studies using the QResearch and CPRD databases (Vinogradova, Y., Coupland, C., & Hippisley-Cox, J., 2020). BMJ, 368, m2571.

SEO Tags: Menopause, Vasomotor Symptoms, Hot Flashes, Night Sweats, Menopausal Hormone Therapy, Transdermal Estrogen, Micronized Progesterone, KNDy Neurons, Thermoregulation, STRAW +10, Integrative Chiropractic, Functional Medicine, Internal Medicine Oversight, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, El Paso TX, Genitourinary Syndrome of Menopause, Bone Health, Cardiovascular Risk, NK3R Antagonists, CBT for Hot Flashes, Personalized Care, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic